Jasper Therapeutics (NASDAQ:JSPR) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Jasper Therapeutics (NASDAQ:JSPR - Free Report) in a report released on Thursday, Benzinga reports. The firm currently has a $65.00 price objective on the stock.

A number of other equities analysts have also weighed in on JSPR. BTIG Research initiated coverage on shares of Jasper Therapeutics in a research note on Monday, July 8th. They issued a "buy" rating and a $90.00 target price for the company. Royal Bank of Canada cut their price target on shares of Jasper Therapeutics from $70.00 to $68.00 and set an "outperform" rating on the stock in a research report on Wednesday, August 14th. JMP Securities restated a "market outperform" rating and issued a $70.00 price objective on shares of Jasper Therapeutics in a report on Tuesday, October 15th. Stifel Nicolaus initiated coverage on Jasper Therapeutics in a report on Thursday, June 27th. They set a "buy" rating and a $86.00 target price on the stock. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Jasper Therapeutics in a research note on Monday, September 9th. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Jasper Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $74.86.

Jasper Therapeutics Stock Performance

NASDAQ:JSPR traded down $0.05 on Thursday, reaching $19.90. The company's stock had a trading volume of 275,668 shares, compared to its average volume of 167,233. Jasper Therapeutics has a 1-year low of $4.00 and a 1-year high of $31.01. The business's 50-day moving average price is $19.31 and its two-hundred day moving average price is $21.22. The firm has a market cap of $299.77 million, a PE ratio of -3.48 and a beta of 2.21.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.09) by $0.12. As a group, sell-side analysts expect that Jasper Therapeutics will post -4.16 EPS for the current year.

Institutional Investors Weigh In On Jasper Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Wolff Wiese Magana LLC bought a new position in shares of Jasper Therapeutics in the third quarter valued at about $59,000. Rhumbline Advisers bought a new position in Jasper Therapeutics in the 2nd quarter valued at about $300,000. Virtu Financial LLC bought a new stake in shares of Jasper Therapeutics during the first quarter worth approximately $306,000. American Century Companies Inc. boosted its holdings in shares of Jasper Therapeutics by 27.1% during the second quarter. American Century Companies Inc. now owns 14,204 shares of the company's stock worth $322,000 after acquiring an additional 3,032 shares during the period. Finally, Concurrent Investment Advisors LLC acquired a new position in shares of Jasper Therapeutics in the first quarter valued at approximately $599,000. Institutional investors and hedge funds own 79.85% of the company's stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.